Kesler Norman & Wride LLC减少了波士顿科学公司的股份,但该公司报告的收入高于分析师的估计。 Kesler Norman & Wride LLC reduced Boston Scientific shares, but the company reported earnings above analyst estimates.

Kesler Norman & Wride LLC及其他机构投资者一直在积极交易波士顿科学公司的股份,Kesler在第四季度将其股份减少了2.6%。 Kesler Norman & Wride LLC and other institutional investors have been actively trading shares of Boston Scientific Co., with Kesler reducing its holdings by 2.6% in the fourth quarter. 尽管有这些交易,波士顿科学公司报告收入丰厚,超过分析师估计的每股0.05美元。 Despite these trades, Boston Scientific reported strong earnings, exceeding analyst estimates by $0.05 per share. 该公司的市场上限为1 496.8亿美元,从分析家那里获得“机动购买”共识评级,平均价格目标为108.91美元。 The company, with a market cap of $149.68 billion, has a "Moderate Buy" consensus rating from analysts and an average price target of $108.91.